PATEL NAIMISH (Chief Medical Officer) sold 16.4% of their position (3.79K shares) of CRISPR THERAPEUTICS AG on the open market
Open‑market sale worth $210.6K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/1/2026ACC: 0001193125-26-251817
Officer· Chief Medical Officer
Since Apr 2025
-3.79K
Net shares
Net seller
$210.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
10K acquired · 13.79K disposed
Non-Derivative Transactions2
Common Shares
Direct
Shares
+10K
Price / share
—
Trade value
—
% of position
76.1%
5/28/2026
13.14K→23.14K
Common Shares
Direct
Shares
−3.79K
Price / share
$55.62
Trade value
$210.58K
% of position
16.4%
5/29/2026
23.14K→19.36K
Total
Net shares
+6.21K
Net value
-$210.58K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 5/28/2026 | M · Option Exercise | +10K | — | — | 76.1% | 13.14K | 23.14K |
| Common Shares Direct | 5/29/2026 | S · Sale | −3.79K | $55.62 | $210.58K | 16.4% | 23.14K | 19.36K |
| Total | +6.21K | -$210.58K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Shares
10K shares
Shares
−10K
Strike price
Held after
20K
Exercisable
—
5/28/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Shares10K shares | 5/28/2026 | M · Option Exercise | −10K | — | 20K |